2483. Twelve-Month Immunogenicity and Safety of an Adjuvanted Recombinant Zoster Vaccine in Immunosuppressed Adults Post Renal Transplant: a Phase III Randomized Clinical Trial

BACKGROUND: The efficacy of the non-live adjuvanted recombinant zoster vaccine (RZV, containing a truncated form of varicella-zoster glycoprotein E [gE] and Adjuvant System AS01(B)) is >90% in adults ≥50 years of age (YOA) (ZOE-50/70) and >68% in hematopoietic stem cell transplant recipients ≥...

Descripción completa

Detalles Bibliográficos
Autores principales: Vink, Peter, Torrell, Josep Maria Ramon, Sanchez-Fructuoso, Ana I, Kim, Sung-Joo, Kim, Sang Il, Zaltzman, Jeffrey, Ortiz, Fernanda, Plana, Josep Maria Campistol, Rodriguez, Ana Maria Fernandez, Rodrigo, Henar Rebollo, Marti, Magda Campins, Perez, Rafael, González-Roncero, Francisco Manuel, Kumar, Deepali, Chiang, Yang-Jen, Doucette, Karen, Pipeleers, Lissa, Morales, Maria Luisa Agüera, Ferrero, Maria Luisa Rodriguez, Secchi, Antonio, McNeil, Shelly A, Campora, Laura, Paolo, Emmanuel Di, Idrissi, Mohamed El, López-Fauqued, Marta, Salaun, Bruno, Heineman, Thomas, Oostvogels, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254944/
http://dx.doi.org/10.1093/ofid/ofy210.2136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254944/
http://dx.doi.org/10.1093/ofid/ofy210.2136

Ejemplares similares